Abstract:Background Lung metastasis is the leading cause of death in patients with osteosarcoma (OS), and new drugs are urgently needed. Epigenetic reprogramming is a recently proposed hallmark of malignancy; therefore, targeting epigenetic enzymes might provide a novel therapeutic strategy for OS lung metastasis. We recently reported that ailanthone (AIL), a natural product isolated from the Chinese medicinal plant Ailanthus altissima, inhibits OS cell growth and induces substantial metabolic changes; however, its direct targets remain unclear. Purpose To identify the direct targets of AIL in OS and to explore the effects of AIL on OS lung metastasis in vivo. Study design Direct target proteins of AIL and downstream signaling pathways were identified in Saos-2 and U-2OS OS cells. The in vivo effects of AIL on OS lung metastasis were investigated using a mouse model. Methods A novel surface plasmon resonance-high-performance liquid chromatography-mass spectrometry (SPR-HPLC-MS) assay was used to determine direct targets of AIL in OS. A cellular thermal shift assay, molecular docking analysis, enzyme activity assay, qRT-PCR, western blotting, chromatin immunoprecipitation assay, and reverse tests were performed to confirm the target and downstream pathway of AIL. A tumor xenograft model was used to verify the efficacy and mechanisms in vivo. Results Histone-lysine N-methyltransferase 2A (KMT2A) together with its scaffold protein menin (MEN1) were identified as direct target proteins of AIL in OS. AIL induced the autophagic degradation of the KMT2A-MEN1 complex. Moreover, AIL inhibited intracellular H3K4 methyltransferase activity and epigenetically inhibited the transcription of genes in the serine biosynthetic pathway (SSP). Furthermore, AIL suppressed OS lung metastasis and downregulated KMT2A, MEN1, and SSP in mouse models. Conclusion This work showed that AIL targets the KMT2A-MEN1 complex and inhibits SSP to suppress OS lung metastasis. Notably, AIL exhibits new mechanisms of action, distinct from those of existing anti-OS drugs. On the basis of these findings, we proposed a novel strategy to treat OS by targeting epigenetic enzymes and cancer metabolism.

2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression By Suppressing Hif-1

Ailanthone Targets the KMT2A-MEN1 Complex to Suppress Lung Metastasis of Osteosarcoma

Methylalpinumisoflavone inhibits hypoxia-inducible factor-1 (HIF-1) activation by simultaneously targeting multiple pathways

Discovery of Novel Aryl Carboxamide Derivatives As Hypoxia-Inducible Factor 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis.

Alantolactone Inhibits Cell Proliferation by Interrupting the Interaction Between Cripto-1 and Activin Receptor Type II A in Activin Signaling Pathway

Synthesis and Anticancer Activity of Novel Actinonin Derivatives As HsPDF Inhibitors

Hypoxia Inducible Factor-1 alpha: A New Anticancer Drug Target

Design, synthesis, and evaluation of novel ursolic acid derivatives as HIF-1α inhibitors with anticancer potential

Anticancer Activity of Natural Flavonoids: Inhibition of HIF-1α Signaling Pathway

Recent Agents Targeting Hif-1 Alpha For Cancer Therapy

Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives

Synthesis and Evaluation of the HIF-1α Inhibitory Activity of 3(5)-Substituted-4-(quinolin-4-yl)- and 4-(2-phenylpyridin-4-yl)pyrazoles As Inhibitors of ALK5.

A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGFβ and FAK Pathways

A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway.

Vanillic Acid Suppresses HIF-1α Expression via Inhibition of mTOR/p70S6K/4E-BP1 and Raf/MEK/ERK Pathways in Human Colon Cancer HCT116 Cells

Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors As a Promising Strategy for Cancer Therapy.

Salinomycin Exerts Anti-Angiogenic and Anti-Tumorigenic Activities by Inhibiting Vascular Endothelial Growth Factor Receptor 2-Mediated Angiogenesis

The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy

A Novel Malate Dehydrogenase 2 Inhibitor Suppresses Hypoxia-Inducible Factor-1 by Regulating Mitochondrial Respiration

Targeting Hypoxia-Inducible Factor-1, for Cancer Treatment: Recent Advances in Developing Small-Molecule Inhibitors from Natural Compounds.

Lipoxin A(4) and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: the Role of Antiangiogenesis